Publications - Page 38 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

Auteurs : Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group.

Sources : Eur Heart J. 2022 Oct 11;43(38):3618-3731.

Plus d'infos

Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed).

Pneumopathies interstitielles diffuses (PID)

Auteurs : Cottin V, Valenzuela C.

Sources : Eur Respir J. 2022 Oct 6;60(4):2201449.

Plus d'infos

Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Pneumopathies interstitielles diffuses (PID)

Auteurs : Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, Voss F, Alves M, Stowasser S, Maher TM; SENSCIS trial investigators.

Sources : ACR Open Rheumatol. 2022 Oct;4(10):837-844.

Plus d'infos

Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.

Pneumopathies interstitielles diffuses (PID)

Auteurs : Khanna D, Distler O, Cottin V, Brown KK, Chung L, Goldin JG, Matteson EL, Kazerooni EA, Walsh SL, McNitt-Gray M, Maher TM.

Sources : J Scleroderma Relat Disord. 2022 Oct;7(3):168-178.

Plus d'infos

Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Pneumopathies interstitielles diffuses (PID)

Auteurs : Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, Voss F, Alves M, Stowasser S, Maher TM; SENSCIS trial investigators.

Sources : ACR Open Rheumatol. 2022 Oct;4(10):837-844.

Plus d'infos

Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats.

Hypertension pulmonaire (HTP)

Auteurs : Tu L, Thuillet R, Perrot J, Ottaviani M, Ponsardin E, Kolkhof P, Humbert M, Viengchareun S, Lombès M, Guignabert C.

Sources : Hypertension. 2022 Oct;79(10):2262-2273.

Plus d'infos

Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.

Hypertension pulmonaire (HTP)

Auteurs : Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, Chaouat A, Cottin V, De Groote P, Favrolt N, Horeau-Langlard D, Magro P, Savale L, Prévot G, Renard S, Sitbon O, Parent F, Trésorier R, Tromeur C, Piedvache C, Grimaldi L, Fadel E, Montani D, Humbert M, Simonneau G.

Sources : Lancet Respir Med. 2022 Oct;10(10):961-971.

Plus d'infos